Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Instead, it operates as a central monoamine modulator offering appetite suppression, mood enhancement, and metabolic impact through neurotransmitter activity
The medication works through a dual mechanism of action that targets two key incretin hormone pathways
Effectiveness in diabetic population As per the non-diabetic model, but reflecting the lower effectiveness for weight loss in the diabetic population
It finished phase 2 trials in 2023, with phase 3 trial results expected to be released before the end of 2025
US$ 22.64
US$ 20.22
US$ 24.70
US$ 23.23
US$ 27.34
